| William A Baron, AUD | |
|
901 Leighton Ave Ste 601, Anniston, AL 36207-5765 | |
| (256) 236-4426 | |
| (256) 238-8830 |
| Full Name | William A Baron |
|---|---|
| Gender | Male |
| Speciality | Qualified Audiologist |
| Experience | 5 Years |
| Location | 901 Leighton Ave Ste 601, Anniston, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609436633 | NPI | - | NPPES |
| 1231A | Other | AL | ABESPA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 1231A (Alabama) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anniston Ear, Nose And Throat, P.c. | 8527081595 | 2 |
News Archive
Cartilage loss is a major component of osteoarthritis (OA), a joint disease that affects over 20 million Americans. In knee OA, cartilage loss is influenced by knee injury, as well as obesity and age. Every healthy knee is supported and protected by a pair of meniscus.
New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.
GenVec, Inc. announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH).
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
EHS Medical Group reported today the addition of 78,000 new members to their Central Valley operations. The growth makes Central Valley the company's single largest region by membership outside of Los Angeles County.
› Verified 8 days ago
| Provider Name | Anniston Ear, Nose & Throat, P.c. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1659489615 PECOS PAC ID: 8527081595 Enrollment ID: O20060105000601 |
News Archive
Cartilage loss is a major component of osteoarthritis (OA), a joint disease that affects over 20 million Americans. In knee OA, cartilage loss is influenced by knee injury, as well as obesity and age. Every healthy knee is supported and protected by a pair of meniscus.
New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.
GenVec, Inc. announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH).
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
EHS Medical Group reported today the addition of 78,000 new members to their Central Valley operations. The growth makes Central Valley the company's single largest region by membership outside of Los Angeles County.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| William A Baron, AUD 901 Leighton Ave Ste 601, Anniston, AL 36207-5765 Ph: (256) 236-4426 | William A Baron, AUD 901 Leighton Ave Ste 601, Anniston, AL 36207-5765 Ph: (256) 236-4426 |
News Archive
Cartilage loss is a major component of osteoarthritis (OA), a joint disease that affects over 20 million Americans. In knee OA, cartilage loss is influenced by knee injury, as well as obesity and age. Every healthy knee is supported and protected by a pair of meniscus.
New research provides exciting insight into the molecular mechanisms associated with addiction and relapse. The study, published by Cell Press in the March 11 issue of the journal Neuron, uncovers a crucial mechanism that facilitates motivation for alcohol after extended abstinence and opens new avenues for potential therapeutic intervention.
GenVec, Inc. announced today that data were presented on GenVec's respiratory syncytial virus (RSV) vaccine program at the International Respiratory Syncytial Virus Symposium, which took place in Rotterdam, Netherlands on December 2-5, 2010. The presentation was given by Barney S. Graham, MD, PhD, Chief, Viral Pathogenesis Laboratory and Chief, Clinical Trials Core, at the Vaccine Research Center (VRC) of the National Institutes of Health (NIH).
CEL-SCI Corporation announced today it has received governmental approval from the Health Authority, Ministry of Health of Ukraine, to begin enrollment of subjects for a Phase III clinical trial of Multikine® in Ukraine. Multikine is the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. Ukraine is one of nine countries to participate in this global Phase III trial. The Phase III trial will be run at about 48 clinical centers, of which about 6 centers will be in Ukraine.
EHS Medical Group reported today the addition of 78,000 new members to their Central Valley operations. The growth makes Central Valley the company's single largest region by membership outside of Los Angeles County.
› Verified 8 days ago
Denise M. Brown, AU.D Audiologist Medicare: Not Enrolled in Medicare Practice Location: 901 Leighton Ave Ste 601, Anniston, AL 36207 Phone: 256-236-4426 Fax: 256-238-8830 | |
Betty Hill Jackson, M.S.,CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 901 Leighton Ave Ste 601, Anniston, AL 36207 Phone: 256-236-4426 Fax: 256-238-8830 | |
Ms. Kimberly Dawn Payne, Audiologist Medicare: Not Enrolled in Medicare Practice Location: 1010 Christine Ave, Suite 250, Anniston, AL 36207 Phone: 256-235-3050 Fax: 256-238-9875 |